8-K: Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Secures $1.4 Billion in Funding

Vaxcyte reported positive topline data for its VAX-31 pneumococcal vaccine candidate in adults, selected it for Phase 3 development, and raised $1.4 billion through a public offering.

Summary

• Vaxcyte announced its third quarter 2024 financial results and provided a business update, highlighting significant progress in its pneumococcal conjugate vaccine (PCV) programs.
• The company reported positive topline safety, tolerability, and immunogenicity data from the Phase 1/2 study of VAX-31 in adults aged 50 and older.
• VAX-31 demonstrated robust immune responses and met or exceeded non-inferiority criteria compared to Prevnar 20 for 20 common serotypes, with some serotypes showing statistically higher responses.
• For the 11 unique serotypes in VAX-31, all doses met superiority criteria.
• Based on these results, VAX-31 was selected to advance to a Phase 3 program for adults, with a pivotal non-inferiority study expected to begin by mid-2025.
• The company also plans to initiate a Phase 2 study of VAX-31 in infants in the first quarter of 2025, pending IND application clearance by the end of 2024.
• Topline data from the primary immunization series of the VAX-24 Phase 2 infant study is expected by the end of the first quarter of 2025.
• Vaxcyte completed a follow-on equity offering, raising $1.4 billion in net proceeds, bringing their total cash, cash equivalents, and investments to $3.3 billion as of September 30, 2024.
• The company incurred $41.3 million in capital and facility buildout expenditures related to its commercial manufacturing suite at Lonza in the third quarter of 2024, with total expenditures of $181.3 million to date.
• Research and development expenses were $116.9 million for the three months ended September 30, 2024, compared to $97.4 million for the same period in 2023.
• The net loss for the third quarter of 2024 was $103.1 million, compared to $92.7 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document is highly positive due to the strong clinical results for VAX-31, the successful capital raise, and the clear path forward for both adult and infant programs. The company's financial position is also very strong. However, the increased net loss and R&D expenses temper the sentiment slightly.

Positives

• The positive topline data for VAX-31 in adults supports its potential as a best-in-class PCV.
• The successful completion of a $1.4 billion follow-on equity offering significantly strengthens Vaxcyte's balance sheet.
• The company is progressing both adult and infant clinical programs for its PCV candidates.
• VAX-31 has the potential to provide over 95% coverage of IPD in U.S. adults.
• The company has a streamlined clinical path for VAX-31 in the pediatric population.
• The VAX-24 Phase 2 study results in adults were published in the journal Vaccine, validating the company's carrier-sparing platform.
• Vaxcyte has a strong cash position of $3.3 billion, providing financial flexibility for future development.

Negatives

• The company reported a net loss of $103.1 million for the third quarter of 2024, an increase from $92.7 million in the same period of 2023.
• Research and development expenses increased to $116.9 million for the third quarter of 2024, up from $97.4 million in the same period of 2023.
• General and administrative expenses also increased to $23.0 million for the third quarter of 2024, up from $15.6 million in the same period of 2023.
• The company has incurred significant capital expenditures of $181.3 million to date for its commercial manufacturing suite.

Risks

• The company's future success depends on the successful development and commercialization of its vaccine candidates.
• There are risks associated with clinical development, including potential delays or inability to obtain regulatory approvals.
• The company's financial performance is subject to risks related to its ability to manage expenses and secure additional funding.
• There are risks associated with manufacturing and scaling up production of its vaccines.
• The company faces competition from other vaccine developers.

Future Outlook

Vaxcyte is focused on advancing its PCV programs, with key milestones including the initiation of Phase 3 studies for VAX-31 in adults, Phase 2 studies for VAX-31 in infants, and data readouts for both VAX-24 and VAX-31 infant studies. The company is also investing in its early-stage pipeline and commercial manufacturing capabilities.

Management Comments

• Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte, stated that they are exceptionally proud of the significant progress made across the adult and infant clinical programs for VAX-31 and VAX-24.
• Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte, noted that the company is well-positioned to maintain continued positive momentum across its PCV franchise after raising $1.4 billion in net proceeds.

Industry Context

This announcement is significant in the context of the pneumococcal vaccine market, where there is a need for vaccines with broader serotype coverage. Vaxcyte's VAX-31 and VAX-24 candidates aim to address this need by targeting both currently circulating and historically prevalent strains. The company's carrier-sparing platform is also a key differentiator in the industry.

Comparison to Industry Standards

• Vaxcyte's VAX-31 is being compared to Prevnar 20 (PCV20), a leading pneumococcal vaccine, in terms of immunogenicity and safety.
• The company's goal is to provide broader coverage than existing PCVs, with VAX-31 targeting over 95% coverage of IPD in U.S. adults, compared to the coverage of existing vaccines.
• The company's carrier-sparing platform is a novel approach compared to traditional vaccine development methods.
• The company is aiming to set a new standard for immunogenicity with its VAX-31 vaccine, with some serotypes showing statistically higher immune responses compared to PCV20.
• The company's focus on both adult and infant indications is aligned with the broader market for pneumococcal vaccines.

Stakeholder Impact

• Shareholders will benefit from the positive clinical results and the strengthened financial position of the company.
• Employees will benefit from the company's growth and continued investment in R&D.
• Customers (healthcare providers and patients) will benefit from the potential availability of new and improved pneumococcal vaccines.
• Suppliers will benefit from the company's increased manufacturing activities.
• Creditors will benefit from the company's strong cash position.

Next Steps

• Initiate a Phase 3 pivotal non-inferiority study for VAX-31 in adults by mid-2025.
• Initiate a Phase 2 study of VAX-31 in infants in the first quarter of 2025, subject to IND clearance.
• Announce topline data from the primary immunization series of the VAX-24 Phase 2 infant study by the end of the first quarter of 2025.
• Announce topline data from the booster dose of the VAX-24 Phase 2 infant study by the end of 2025.
• Announce topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 study in 2026.
• Announce topline safety, tolerability, and immunogenicity data from the VAX-31 infant Phase 2 study primary three-dose immunization series in mid-2026.

Key Dates

Keywords

Vaxcyte, VAX-31, VAX-24, Pneumococcal Conjugate Vaccine, PCV, Vaccine, Clinical Trials, Immunogenicity, Phase 3, Phase 2, FDA, Infectious Disease, Public Offering, Biotechnology